Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Multicenter Study
. 2022 Oct;49(10):970-978.
doi: 10.1111/1346-8138.16517. Epub 2022 Jul 20.

Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study

Hidehisa Saeki  1 , Yasumasa Kanai  2 , Kenta Murotani  3 , Kei Ito  4 , Takuya Miyagi  5 , Hidetoshi Takahashi  6 , Yayoi Tada  7 , Mari Higashiyama  8 , Yuki Hashimoto  9 , Hiroki Kitabayashi  2 , Shinichi Imafuku  10
Affiliations
Multicenter Study

Work productivity in real-life employed patients with plaque psoriasis: Results from the ProLOGUE study

Hidehisa Saeki et al. J Dermatol. 2022 Oct.

Abstract

Psoriasis poses a substantial economic burden by reducing the work productivity of affected patients. We aimed to evaluate the negative impact of plaque psoriasis on work productivity and effectiveness of brodalumab in improving work productivity impairment in real-life employed patients. This analysis was conducted in employed patients from ProLOGUE, an open-label, multicenter, prospective cohort study (Japan Registry of Clinical Trials identifier: jRCTs031180037). Outcomes included association of Work Productivity and Activity Impairment-Psoriasis (WPAI-PSO) domain scores with scores from various patient-reported outcome measures or Psoriasis Area and Severity Index (PASI) scores at baseline. Change from baseline in WPAI-PSO domain scores following brodalumab treatment was also evaluated. Of the 73 patients enrolled, 51, 48, and 40 patients were considered employed at baseline, Week 12, and Week 48 of brodalumab treatment, respectively. In the model adjusted by age and sex, the work productivity loss score correlated with the Dermatology Life Quality Index (DLQI), itch Numeric Rating Scale (NRS), Patient Health Questionnaire-8 (PHQ-8), and skin pain NRS scores (partial Spearman correlation coefficient [ρ] = 0.608, 0.510, 0.461, and 0.424, respectively); presenteeism score correlated with the DLQI, itch NRS, and skin pain NRS scores (ρ = 0.568, 0.500, and 0.403, respectively); and activity impairment score correlated with the DLQI and PHQ-8 scores (ρ = 0.530 and 0.414, respectively). None of the WPAI-PSO domain scores correlated with the PASI score. All WPAI-PSO domain scores (except absenteeism) significantly reduced from baseline to Weeks 12 (p < 0.0001) and 48 (p < 0.001) with brodalumab treatment. In conclusion, work productivity impairment in psoriasis was associated with various subjective symptoms that can be captured using patient-reported outcome measures. Brodalumab treatment improved work productivity in real-life employed patients with plaque psoriasis.

Keywords: brodalumab; employment; patient-reported outcome measures; psoriasis; work performance.

PubMed Disclaimer

Conflict of interest statement

H. Saeki reports grants from Kyowa Kirin during the study period; grants, personal fees, and nonfinancial support from Kyowa Kirin, Mitsubishi Tanabe Pharma, Taiho Pharmaceutical, Maruho, TOKIWA Pharmaceutical, Torii Pharmaceutical, and Eisai outside the submitted work; and personal fees and nonfinancial support from Sanofi, Celgene, and KYORIN Pharmaceutical outside the submitted work. Y. Kanai is an employee of Kyowa Kirin. K. Murotani reports grants from Kyowa Kirin during the study period. K. Ito reports grants from Kyowa Kirin during the study period and personal fees from Kyowa Kirin, Mitsubishi Tanabe Pharma, Sato Pharmaceutical, Ushio, Amgen, Janssen Pharmaceutical, AbbVie, Eisai, Sanofi, Eli Lilly Japan, Maruho, Nippon Kayaku, Taiho Pharmaceutical, and Novartis Pharma outside the submitted work. T. Miyagi reports grants from Kyowa Kirin during the study period; grants, personal fees, and nonfinancial support from AbbVie, Kaken Pharmaceutical, Maruho, Boehringer Ingelheim, Eisai, Celgene, Eli Lilly Japan, Novartis Pharma, and Taiho Pharmaceutical outside the submitted work; grants and personal fees from Daiichi Sankyo, Sanofi, Ono Pharmaceutical, Mitsubishi Tanabe Pharma, and Otsuka Pharmaceutical outside the submitted work; personal fees and nonfinancial support from Janssen Pharmaceutical; grants from Actelion, Earth Corporation, Teijin Pharma, LEO Pharma, and Sato Pharmaceutical outside the submitted work; and personal fees from CSL Behring outside the submitted work. H. Takahashi reports grants from Kyowa Kirin during the study period. Y. Tada reports grants from Kyowa Kirin during the study period; grants, personal fees, and nonfinancial support from Kyowa Kirin, Eli Lilly Japan, AbbVie, Maruho, Celgene, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma, Novartis Pharma, Sanofi, UCB Japan, Torii Pharmaceutical, LEO Pharma, Eisai, Kaken Pharmaceutical, Pfizer, Ushio, Meiji Seika Pharma, Nippon Boehringer Ingelheim, JIMRO, Bristol Myers Squibb, and TOKIWA Pharmaceutical outside the submitted work; grants and nonfinancial support from Kanebo Cosmetics, MSD, Ono Pharmaceutical, Pola Pharma, Nihon Pharmaceutical, Smith & Nephew, and Sato Pharmaceutical outside the submitted work; personal fees and nonfinancial support from Janssen Pharmaceutical outside the submitted work; grants from Japan Blood Products Organization, Mochida Healthcare, Oshimatsubaki, and Shionogi outside the submitted work; and personal fees from Chugai Pharmaceutical outside the submitted work. M. Higashiyama reports grants from Kyowa Kirin during the study period; personal fees and nonfinancial support from LEO Pharma outside the submitted work; and personal fees from Kyowa Kirin, AbbVie, Celgene, Taiho Pharmaceutical, Torii Pharmaceutical, Mitsubishi Tanabe Pharma, Eli Lilly Japan, Novartis Pharma, Maruho, and Janssen Pharmaceutical outside the submitted work. Y. Hashimoto reports grants from Kyowa Kirin during the study period and personal fees from Kyowa Kirin, Eisai, AbbVie, Eli Lilly Japan, Nippon Kayaku, Janssen Pharmaceutical, Taiho Pharmaceutical, Torii Pharmaceutical, LEO Pharma, Maruho, UCB Japan, Novartis Pharma, and Celgene outside the submitted work. H. Kitabayashi is an employee of Kyowa Kirin and owns stock in the company. S. Imafuku reports grants from Kyowa Kirin during the study period; grants and personal fees from AbbVie, Eisai, Kaken Pharmaceutical, Kyowa Kirin, Sato Pharmaceutical, Sanofi, Taiho Pharmaceutical, Mitsubishi Tanabe Pharma Corporation, Tsumura, Torii Pharmaceutical, Nippon Zoki Pharmaceutical, Novartis Pharma, Maruho, and LEO Pharma outside the submitted work; grants from Pola Pharma outside the submitted work; and personal fees from Astellas, Eli Lilly Japan, MSD, Otsuka Pharmaceutical, Ono Pharmaceutical, Sun Pharma, GSK, JIMRO, Celgene, Daiichi Sankyo, Sumitomo Dainippon Pharma, Takeda Pharmaceutical, Japan Blood Products Organization, Pfizer, Bristol Myers Squibb, Meiji Seika Pharma, Janssen Pharmaceutical, and UCB Japan outside the submitted work.

Figures

FIGURE 1
FIGURE 1
Patient disposition. “Employed” refers to patients who responded “yes” to question 1 of the WPAI‐PSO questionnaire. “Other” refers to patients who responded “no” to question 1 of the WPAI‐PSO questionnaire. WPAI‐PSO, Work Productivity and Activity Impairment‐Psoriasis.
FIGURE 2
FIGURE 2
Work productivity impairment in employed patients at baseline. Data represent patients with work productivity impairment (WPAI‐PSO score >0.0%) in the absenteeism or presenteeism domains. WPAI‐PSO, Work Productivity and Activity Impairment‐Psoriasis.
FIGURE 3
FIGURE 3
Change from baseline in the WPAI‐PSO domain scores: (a) baseline vs Week 12 in all employed patients, (b) baseline vs Week 48 in all employed patients, (c) baseline vs Week 12 in employed patients with impaired WPAI‐PSO domain score (>0.0%) at baseline, and (d) baseline vs Week 48 in employed patients with impaired WPAI‐PSO domain score (>0.0%) at baseline. Top whisker represents Q3 + (1.5 × IQR) or the maximum, whichever is lower; bottom whisker represents Q1 − (1.5 × IQR) or the minimum, whichever is higher; top border of the box represents Q3; bottom border of the box represents Q1; middle (bolded) line of the box represents the median. IQR, interquartile range; Q, quartile; WPAI‐PSO, Work Productivity and Activity Impairment‐Psoriasis.
FIGURE 4
FIGURE 4
Change in income opportunity loss (loss of annual income per person) because of WPL from baseline to Week 48 in all employed patients. Top whisker represents Q3 + (1.5 × IQR) or the maximum, whichever is lower; bottom whisker represents Q1 – (1.5 × IQR) or the minimum, whichever is higher; top border of the box represents Q3; bottom border of the box represents Q1; middle (bolded) line of the box represents the median. IQR, interquartile range; Q, quartile; WPL, work productivity loss.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. AlQassimi S, AlBrashdi S, Galadari H, Hashim MJ. Global burden of psoriasis ‐ comparison of regional and global epidemiology, 1990 to 2017. Int J Dermatol. 2020;59:566–71. - PubMed
    1. Kubota K, Kamijima Y, Sato T, Ooba N, Koide D, Iizuka H, et al. Epidemiology of psoriasis and palmoplantar pustulosis: a nationwide study using the Japanese national claims database. BMJ. 2015;5:e006450. - PMC - PubMed
    1. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol. 1999;41:401–7. - PubMed
    1. Chen KC, Hung ST, Yang CW, Tsai TF, Tang CH. The economic burden of psoriatic diseases in Taiwan. J Dermatol Sci. 2014;75:183–9. - PubMed
    1. Villacorta R, Teeple A, Lee S, Fakharzadeh S, Lucas J, McElligott S. A multinational assessment of work‐related productivity loss and indirect costs from a survey of patients with psoriasis. Br J Dermatol. 2020;183:548–58. - PMC - PubMed

Publication types

Grants and funding